May 18th at 5pm (GMT) – Hybrid Format
Chair: Vitor Costa, ICBAS
Title: Could we narrow the existing gap between experimental models and clinical evidence in systemic amyloidosis?

 

 

Vittorio Bellotti is a medically qualified scientist specialized in internal medicine and protein biochemistry who has worked on protein misfolding disorders in Italy, USA and UK for over 30 years. 

His seminal demonstration that the amyloidogenic variants of lysozyme, discovered in the laboratory of Professor Sir Mark B. Pepys FRS at the Royal Postgraduate Medical School, Hammersmith Hospital in 1993, were less stable than the wild type molecule provided the basis for a now generally accepted theory explaining the dynamic mechanism of amyloid conversion of globular proteins. In 1995 he established an independent group at the University of Pavia carrying out pioneering work on β2-microglobulin fibrillogenesis causing dialysis-related amyloidosis. He has also continued his association with the Pepys laboratory and was central to the identification of the transthyretin superstabiliser, mds84, and the subsequent collaboration with GlaxoSmithKline to develop this material as a potential therapy for transthyretin related amyloidosis.He joined UCL in October 2011 as Professor of Medical Biochemistry and established a new group at the Centre for Amyloidosis and Acute Phase Proteins. 

Throughout his career he has been inspired by the idea that the most successful way to identify the underlying causes of complex diseases, such as systemic amyloidosis, derives from the collaboration between basic scientists, pathologists and research-oriented clinicians.

Subscribe

Are you ready to take the next step toward your future career?